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Several rare mutations in the melanocortin-4 receptor gene (MC4R) predispose to obesity. For the most common
missense variant V103I (rs2229616), however, the previously reported similar carrier frequencies in obese andnonobese
individuals are in line with in vitro studies, which have not shown a functional implication of this variant. In the
present study, we initially performed a transmission/disequilibrium test on 520 trios with obesity, and we observed
a lower transmission rate of the I103 allele ( ), which was an unexpected ﬁnding. Therefore, we initiatedPp .017
two large case-control studies ( and ) and combined the data with those from 12 publishedNp 2,334 Np 661
studies, for a total of 7,713 individuals. The resulting meta-analysis provides evidence for a negative association
of the I103 allele with obesity (odds ratio 0.69; 95% conﬁdence interval 0.50–0.96; ), mainly comprisingPp .03
samples of European origin. Additional screening of four other ethnic groups showed comparable I103 carrier
frequencies well below 10%. Genomic sequencing of the MC4R gene revealed three polymorphisms in the noncoding
region that displayed strong linkage disequilibrium with V103I. In our functional in vitro assays, the variant was
indistinguishable from the wild-type allele, as was the result in previous studies. This report on an SNP/haplotype
that is negatively associated with obesity expands the successful application of meta-analysis of modest effects in
common diseases to a variant with a carrier frequency well below 10%. The respective protective effect against
obesity implies that variation in the MC4R gene entails both loss and gain of function.
Mutation screens of the melanocortin-4-receptor gene
(MC4R [MIM 155541]) have been performed by several
groups on the basis of samples of obese subjects and lean
control individuals (Gotoda et al. 1997; Gu et al. 1999;
Ohshiro et al. 1999; Farooqi et al. 2000, 2003; Vaisse
et al. 2000; Dubern et al. 2001; Jacobson et al. 2002;
Branson et al. 2003; Marti et al. 2003; Hinney et al.
2003). The respective probands are mostly of European
origin. The MC4R gene is part of the melanocortinergic
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pathway that controls energy homeostasis. Functional
data indicate that many of the missense, nonsense and
frameshift mutations reported elsewhere result in either
a reduced function or a total loss of function (Yeo et al.
2003). Furthermore, transmission disequilibriumbetween
obesity (MIM 601665) and functionally relevant MC4R
mutations has recently been demonstrated in 520 trios
(Hinney et al. 2003).
The V103I polymorphism, ﬁrst described in 1997 (Go-
toda et al. 1997), is the most common MC4R variant,
with allele frequencies 11% in almost all studied popu-
lations. Pharmacological studies have not detected a func-
tional difference between the receptor comprising an iso-
leucine at position 103 and the wild-type receptor (Gu
et al. 1999; Vaisse et al. 2000; Hinney et al. 2003).
Systematic differences in frequencies of the I103 allele
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Figure 1 ORs of the single studies and the meta-analysis (logarithmic scale)
between obese subjects and lean control individuals have
not been observed. Only one study (Rosmond et al. 2001)
has explicitly reported that individuals with the I103 al-
lele have lower body mass indices (BMIs) (24.1 kg/m2 vs.
26.3kg/m2; ), lower waist-to-hip ratios (0.89 vs.Pp .054
0.94; ), and lower abdominal sagittal diameterPp .023
(21.0 vs. 22.7; ).Pp .095
Our current study is based on the unexpected observa-
tion of a reduced transmission of the I103 allele in 520
obese trios: we detected 35 heterozygous parents, only
10 of whom transmitted the I103 allele to their offspring
( ), suggesting that this allele is protective againstPp .017
obesity. For heterozygous carriers, we estimated the re-
spective genotype relative risk of developing obesity as
0.40 (exact 95% CI 0.17–0.86). The respective popu-
lation attributable risk was 0.03—which means that
the prevalence of obesity would increase by 3% if no
I103 carriers were in the population—which is rather
high for the observed carrier frequency, reﬂecting the
relatively large effect estimate of this variant.
On the basis of these results, we screened two large
German study groups ascertained in Augsburg, in south-
ern Germany, and Essen, in the Ruhr area, for the V103I
polymorphism, and we combined all available informa-
tion on obese and nonobese individuals in ameta-analysis.
The two studies showed consistent results for the I103
allele, with odds ratios (ORs) of 0.58 (95%CI 0.29–1.16)
and 0.69 (95% CI 0.29–1.65), respectively (table 1); the
moderate effect and the imbalance in the number of obese
and nonobese individuals resulted inP values1.05 in these
quite large studies. For the meta-analysis, we combined
these data with all previously published data on V103I
status in obese and nonobese individuals of the same re-
spective ethnicity (table 1). Whereas 11 of the 14 studies
display a higher percentage of I103 carriers in the non-
obese group, none of the 95% CIs for the OR excludes
1. The meta-analysis results in an OR of 0.69 (95% CI
0.50–0.96) with a P value of .03, thus providing evidence
for a negative association between the I103 allele and
obesity. Figure 1 shows the large CIs of the ORs for every
single study and the small CI for the meta-analysis. The
consistency of these results is underlined by the fact that
all CIs overlap and contain the OR estimate of the meta-
analysis. Additionally, we performed the Breslow-Day test
(Breslow and Day 1980) for homogeneity of the ORs,
where the null hypothesis of homogeneitywas not rejected
( ). We also analyzed the subgroup of whites, whoPp .88
account for 12 of the 14 study groups and an even larger
proportion of subjects; the results were very similar (OR
0.71; 95% CI 0.50–0.99).
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Table 2
BMI Percentiles P50 and P90 and I103 Carrier Frequencies for the KORA Study Group from Augsburg, Germany
AGE
CATEGORY
(YEARS)
FINDING IN FEMALES FINDING IN MALES
P50
(kg/m2)
P90
(kg/m2)
Proportion (%)
of Probands
with I103
and BMI P50
Proportion (%)
of Probands
with I103
and BMI 1P90
P50
(kg/m2)
P90
(kg/m2)
Proportion (%)
of Probands
with I103
and BMI P50
Proportion (%)
of Probands
with I103
and BMI 1P90
25–29 22.6 30.0 4/79 (5.1%) 0/17 (.0%) 24.8 29.3 1/70 (1.4%) 0/14 (.0%)
30–34 24.0 31.8 1/114 (.9%) 0/22 (.0%) 25.5 30.4 6/118 (5.1%) 3/24 (12.5%)
35–39 24.4 31.3 8/113 (7.1%) 1/23 (4.4%) 26.6 31.0 5/102 (4.9%) 0/21 (.0%)
40–44 24.2 32.3 3/97 (3.1%) 1/20 (5.0%) 26.6 31.4 4/92 (4.4%) 0/17 (.0%)
45–49 26.1 34.0 2/106 (1.9%) 0/22 (.0%) 27.2 32.9 5/100 (5.0%) 0/20 (.0%)
50–54 26.7 34.6 4/101 (4.0%) 0/17 (.0%) 27.9 34.3 2/104 (1.9%) 2/21 (9.5%)
55–59 27.4 35.5 7/92 (7.6%) 0/15 (.0%) 27.2 32.4 1/107 (.9%) 0/20 (.0%)
60–64 28.1 34.8 6/107 (5.6%) 1/22 (4.6%) 28.0 33.5 3/103 (2.9%) 0/18 (.0%)
65–69 29.5 36.2 1/99 (1.0%) 0/19 (.0%) 28.1 34.4 8/89 (9.0%) 0/19 (.0%)
70–74 28.6 34.3 3/72 (4.2%) 0/14 (.0%) 28.6 33.0 4/86 (4.7%) 1/18 (5.6%)
A drawback of our study is the use of different criteria
to deﬁne obese and nonobese individuals in the different
studies (table 1). Some studies (e.g., Gotoda et al. [1997],
Jacobson et al. [2002], andMarti et al. [2003])were based
on rather low BMI thresholds for obesity, whereas others
(e.g., Vaisse et al. [2000] and Dubern et al. [2001]) in-
cluded only morbidly obese patients. Nevertheless, most
of the studies with weaker inclusion criteria mainly per-
tain to rather severely obese probands, as indicated by
mean BMI well over 35 kg/m2 (Jacobson et al. 2002;
Marti et al. 2003); similar differences apply to the deﬁ-
nitions of nonobese individuals. Another limitation of this
meta-analysis is that age and sex effects cannot readily
be addressed, because the respective phenotypic infor-
mation was not provided for V103I status in all studies.
In our large Augsburg sample, the distribution of I103
carriers does not differ considerably by sex or age (table
2). We do not perceive that publication bias, a usual con-
cern in meta-analysis, has an impact on our analysis, be-
cause almost all of the included studies analyzed and re-
ported all variants in the MC4R gene and did not
speciﬁcally investigate the association between the V103I
polymorphism and obesity.
Given the population-based sample fromAugsburg, we
were able to estimate the effect of the I103 allele, in terms
of BMI. In the total sample of 3,872 individuals, 139 (67
females) were I103 carriers (mean BMI kg/26.71 4.08
m2; mean age years), including one ho-48.48 14.04
mozygous male (BMI 23.89 kg/m2; age 33 years); 3,733
(1,886 females) individuals were homozygous for V103
(mean BMI kg/m2; mean age27.23 4.73 49.14
years). Sex- and age-adjusted regression analysis13.88
resulted in an effect estimate of 0.48 kg/m2 for I103
carrier status ( ), which is equivalent to a reduc-Pp .22
tion of 1.6 kg in a 1.8-m–tall individual. BMI is a com-
plex trait inﬂuenced by many genes and environmental
factors; we assume that, similar to the predictive testing
for venous thrombosis (Yang et al. 2003), knowledge of
such polygenes will enable prediction of BMI.
Because of the few studies based on nonwhite popu-
lations, we determined the carrier frequencies for I103
in Tanzanians (5.2%; 95% CI 1.7%–11.7%), African
Americans (6.3%; 95% CI 2.3%–13.1%), Chinese
(6.5%; 95% CI 2.4%–13.7%), and Japanese (0.0%,
95% CI 0.0%–3.8%). Since I103 carriers in the Japanese
population have been reported elsewhere (Ohshiro et al.
1999), the results indicate that carriers are present at a
frequency well below 10% in all these populations. Se-
quence comparison of human MC4R to its rodent, pig,
and cattle homologues reveals that, in those species,
MC4R encompasses a valine at position 103 (Alvaro et
al. 1996; Kim et al. 2000; Dumont et al. 2001; Haege-
man et al. 2001).
To address functional implications of the observed as-
sociation, two approaches were taken:
1. To detect other potentially functionally relevant
SNPs that are in linkage disequilibrium with the V103I
polymorphism, we screened the MC4R coding region,
as well as 1,676 bp upstream and 1,330 bp downstream,
by use of genomic sequencing in 10 individuals whowere
heterozygous and 2 individuals who were homozygous
for either the I103 or the wild-type allele. Six SNPs (ﬁve
novel) were identiﬁed, three of which (SNP001745710,
SNP001745711, and SNP002901655) were completely
genotyped in 501 trios. Transmission/disequilibrium test
(TDT) analysis revealed that none of these SNPs showed
substantially stronger transmission disequilibrium than
did V103I (table 3). I103 always formed a haplotype
with their less-frequent alleles. When we consider the
results for this haplotype, we can almost rule out that
the observed transmission disequilibrium was caused by
undetected heterozygous offspring in the trios, which
can result in an overtransmission of the common allele
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Table 3
TDT Analysis in 501 Trios
MARKER
NO. OF PROBANDS
WITH ALLELE
PTransmitted Not Transmitted
V103I: A allele 9 24 .014
SNP001745710: T allele 9 25 .009
SNP001745711: T allele 34 43 .362
SNP002901655: G allele 9 24 .014
Haplotype V103I-001745710-001745711-002901655:
G-C-C-C 43 33 .302
G-C-T-C 24 18 .441
G-T-C-C 0 1 1
A-T-T-G 9 24 .014
(Mitchell et al. 2003). The functional role of the detected
SNPs remains unclear. Each of the four SNPs, further
SNPs outside of the resequenced segment, or combi-
nations thereof could underlie the observed association.
None of the SNPs located upstream of the MC4R coding
sequence resides in the essential promoter region deﬁned
in mice (Dumont et al. 2001). However, a basal promoter
element within position 430 to 1,600 from the trans-
lation start of MC4R has been reported (Lamar and Kes-
terson 2002); all upstream SNPs are located within this
region.
2. We performed functional studies. For functional
characterization, COS-7 cells were transiently transfected
with MC4R-V103 and I103 in two independent labs.
Intracellular cAMP accumulation was determined after
stimulation with a-MSH in both labs and additionally
with NDP-a-MSH and b-MSH in one lab. Basal cAMP
values were found to be indistinguishable in cells express-
ing either thewild-type allele or I103. Stimulation ofV103
and I103with all three agonists did not result in consistent
differences in maximal stimulation and EC50 values. Fur-
thermore, binding properties of both variants are indis-
tinguishable. In conclusion, we found no consistent dif-
ferences in the in vitro test systems; our ﬁndings are in
line with previous studies (Gu et al. 1999; Vaisse et al.
2000). However, these results obtained in transient over-
expression systems do not rule out quantitatively minor
differences in the employed systems, differences in recep-
tor expression, and signaling properties in other test sys-
tems and/or under physiological conditions.
In this study, we have shown that an MC4R polymor-
phism is negatively associated with obesity. We initially
detected a signiﬁcantly reduced transmission rate of I103
in 520 obese trios. Conﬁrming this effect was possible
only by performing two new association studies and in-
corporating them in a meta-analysis of all published
studies, which resulted in an OR of 0.69 (95% CI 0.50–
0.96; ). It should be noted that none of the in-Pp .03
dividual studies had rendered a P value .05. With as-
sumed carrier frequencies of 2% in obese and 3% in
nonobese individuals and a resulting moderate effect of
, the mean power of the individual studiesORp 0.66
was only 10% (minimum 4%; maximum 20%). On the
other hand, an unstratiﬁed analysis with the number of
case and control individuals included in our meta-analy-
sis results in a power of 80%.
On the basis of the total loss of function or the reduced
function detected for those MC4R mutations involved in
obesity, it seems conceivable that the relevant SNP/hap-
lotype causes a gain of function ofMC4R. Thus, variants
in this gene would cover a functional spectrum ranging
from loss to moderate gain of function. Single loss-of-
function mutations often result in BMIs 140 kg/m2 and
are mainly reported in only one or two pedigrees world-
wide. On the other hand, the effect of the more common
variant I103 is rather low; clearly, carriers do not present
with an extremely lean phenotype.
To our knowledge, only three large-scale meta-analyses
for obesity have been performed to date; the minor allele
frequencies of the investigated SNPs were all 115%. The
ﬁrst meta-analysis pertaining to the Trp64Arg polymor-
phism in the b3 adrenergic receptor (Allison et al. 1998)
was not signiﬁcant (BMI difference between Trp/Trp ho-
mozygotes and Trp/Arg heterozygotes: 0.19 kg/m2; Pp
), whereas a later analysis (Fujisawa et al. 1998) that.07
included more individuals showed a signiﬁcant BMI dif-
ference, between carriers and noncarriers of the Arg allele,
of 0.30 kg/m2 (95% CI 0.13–0.47 kg/m2). For leptin re-
ceptor (LEPR) polymorphisms (Heo et al. 2002), meta-
analysis revealed no association. There is an ongoing de-
bate as to whether common (allele frequency 11%) or
rare variants are more likely to be involved in complex
disorders (Pritchard 2001; Lohmueller et al. 2003). Our
study, which was based on an average I103 carrier fre-
quency of 2.1% in 3,631 obese subjects and 3.5% in
4,082 nonobese control individuals (table 1), is a good
example that meta-analysis is a powerful tool for investi-
gating even moderate effects of common variants on sus-
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ceptibility to common disease. The potential contribution
of rare variants with a moderate effect to common dis-
orders has to be challenged in even-larger studies.
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Appendix A
Primers for Genomic Sequencing of 4.005 bp
of the MC4R Locus*
Upstream:
Primers in PCR1:
F: GAAGGGAGTTGGAGGTGTGA
R: GCACCCTCCATCAGAGTAGC
Primers in PCR2:
1F: GATATGGTCCTGCCACCTG
1R: GGTGGTTTGAAAGATGGCAG
2F: GAAAGAGGATACATTCCCAACC
2R: ATGAATGGGTTCAAAAGGGG
3F: TGTCGGTTCAACTTACGATACG
3R: AAGCTATCTTCAGGCAGCCA
3S: TTTCCTGAGTTCAGTGTAAGCA
4F: TGAACCACTACTGGCTGGGT
4R: GCTTTGAGTGTTAGGGGCTG
5F: CAGTCTCTTATCCGGCTTGC
5R: CCATGCCTGCTGTGAGTAAA
6F: GCACAGATTCGTCTCCCAAT
6R: GCCTTTTCCAAGGGACTCAC
Coding sequence:
Primers in PCR1:
F: GCACAGATTCGTCTCCCAAT
R: TGTTACGAAAGCACGCAAAG
Primers in PCR2:
7F: GCATGGCAGCTTCAAGGA
7R: GCACCCTCCATCAGAGTAGC
* Primer 3S replaced primer 3R in the sequencing reaction of the
PCR product obtained with primers 3F and 3R.
8F: TGCACACTTCTCTGCACCTC
8R: CCAACCCGCTTAACTGTCAT
9F: GTAGCTCCTTGCTTGCATCC
9R: CGGAGTGCATAAATCAGAGG
10F: GGCCAGGCTTCACATTAAGA
10R: ACGGAAGAGAAAGCTGTTGC
Downstream:
Primers in PCR1:
F: CCGGAGTCAAGAACTGAGGA
R: TTGCATATGACTTCTGCCCA
Primers in PCR2:
11F: CATCTGTTGCTATCCCCTGG
11R: TGTTACGAAAGCACGCAAAG
12F: GCCCAGTCTCTGTATTATTTCCA
12R: CAGGCTGTTTGCTAAGGGAG
13F: AGGTTTGTTCATCCTCCCTG
13R: TTGCCAGAAAACACTTCTGC
14F: GGATTCAGGGTCTGCTGAAG
14R: ACTTCTGCCCATGAGCATTT
Appendix B
Study Groups
Marburg: The 520 obese trios were recruited via obese
children and adolescents who had a BMI 190th sex- and
age-speciﬁc percentile, as reported elsewhere (Hinney et
al. 2003).
Augsburg: The KORA Survey 2000 is a representative
sample of the adult general population of German na-
tionality and comprises 4,261 individuals aged 25–74
years (Filipiak et al. 2001). Because of the variation in
BMI over this age span, sex-speciﬁc 5-year groups (from
25–29 years to 70–74 years) were built, and the 50th and
90th percentiles in these age groups (P50 and P90, re-
spectively) were calculated. Individuals were considered
to be nonobese if their BMI was P50 and to be obese
when their BMI was 1P90. This resulted in a total of
1,951 nonobese and 383 obese genotyped individuals;
some individuals could not be included, owing to failed
genotyping or missing BMI values.
Essen: There were 489 obese and 172 nonobese indi-
viduals aged 18–65 years, with BMIs 30 kg/m2 (mean
kg/m2) and !25 kg/m2 (mean kg/41.6 8.8 22.7 1.6
m2), respectively, as described elsewhere (Herpertz et al.
2003).
Additional ethnicities: Blood from Tanzanians was ran-
domly collected from patients of a local hospital in Dar-
essalam ( ). Blood from African Americans wasNp 96
obtained at the Blood Bank of San Bernadino and Riv-
erside Counties, CA ( ). Blood from Chinese sub-Np 96
jects was obtained from voluntary students of the Tech-
nical College of Wuhan, People’s Republic of China
( ). Blood from Japanese was obtained at Gifu,Np 92
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Japan ( ). All blood samples were taken in orderNp 95
to study SNP distributions in different ethnicities (Siffert
et al. 1999); anthropometrical data were not available.
Appendix C
Genotyping
Genotyping of the KORA S 2000 study group from
Augsburg was performed in the GenomeAnalysis Center
of the GSF. Analyses were performed using the Mass-
ARRAY system (Sequenom). In brief, genomic DNAs
were ampliﬁed by PCR by use of HotStarTaq DNAPoly-
merase (Qiagen). Genotyping assays were performed by
use of 5 ng of genomic DNA. PCR primers were used
at 167 nM ﬁnal concentrations, for a PCR volume of 6
ml. The following primers were used: PCR: 5′-ACGTTG-
GATGGATATGCTGGTGAGCGTTTC-3′ and 5′-ACG-
TTGGATGACTCTGTGCATCCGTATCTG-3′.
Extension reaction was performed with the following
primer: 5′-GTTTCAAATGGATCAGAAACCATT-3′.
The PCR condition was 95C for 15 min for hot start,
followed by denaturing at 95C for 30 s, annealing at
56C for 30 s, extension at 72C for 1 min for 44 cycles,
and, ﬁnally, incubation at 72C for 10 min. PCR products
ﬁrst were treated with shrimp alkaline phosphatase (SAP)
(Amersham) for 20 min at 37C to remove excess dNTPs
and, afterward, for 10 min at 85C to inactivate SAP.
ThermoSequenase (Amersham) was used for the base ex-
tension reactions. Extension primers were at a ﬁnal con-
centration of 0.54 mM in 10ml reactions. The base exten-
sion reaction condition was 94C for 2 min, followed by
94C for 5 s, 52C for 5 s, and 72C for 5 s for 40 cycles.
All reactions (reverse transcription, PCR ampliﬁcation,
and base extension) were performed in a Tetrad PCR
thermal cycler (MJ Research). The ﬁnal base extension
products were treated with SpectroCLEAN resin (Seque-
nom) to remove salts in the reaction buffer. This step was
performed with a Multimek 96-channel autopipette
(Beckman Coulter), and 16 ml of resin-water suspension
was added into each base extension reaction, making the
total volume 26 ml. After a quick centrifugation (2,000
rpm, 3 min) in an Eppendorf Centrifuge 5810, 10 nl of
reaction solution was dispensed onto a 384-format
SpectroCHIP (Sequenom) prespotted with a matrix of 3-
hydroxypicolinic acid (3-HPA) by use of a SpectroPoint
nanodispenser (Sequenom). A modiﬁed Bruker Biﬂexma-
trix-assisted laser desorption ionization-time-of-ﬂight
SpectroCHIPmass spectrometer (Sequenom) was used for
data acquisitions from the SpectroCHIP. Genotyping calls
were made in real time with MASSARRAY RT software
(Sequenom).
For study groups from Marburg, Essen, and additional
ethnicities, genotyping was performed by PCR with sub-
sequent diagnostic RFLP analyses, or, for alleles that did
not alter restriction sites, speciﬁc primers were designed
to perform allele-speciﬁc PCR reactions (tetra-ARMS (Ye
et al. 2001); V103I was detected as described elsewhere
(Gotoda et al. 1997). In detail: SNP001745710,
SNP001745712, SNP001745713, and SNP002901655
were genotyped by tetra-ARMS-PCR (Ye et al. 2001).
Primers were as follows: (a) SNP001745710 CrT;
MC4R-710-FiC 5′-GTTACTAGGTATTTGTCGGTTC-
AACTGAC-3′ and MC4R-710-Ro 5′-TGAGGAGTTTG-
TGTTATAGCTGAAAAAA-3′ 198-bp amplicon detects
the SNP001745710 C-allele; MC4R-710-RiT 5′-TTTAA-
ACCTCCAGAGTTTAACGTAGCA-3′ and MC4R-710-
Fo 5′-TTAACCCTGAAATAAGCAGCTACAAACT-3′
260-bp amplicon detects the SNP001745710 T-allele.
Amplicon length of the two outer primers (MC4R-710-
Fo and MC4R-710-Ro) was 402 bp. (b) SNP001745712
CrT; MC4R-712-FiC 5′-GAAATATGGGATATTAGT-
GCATTAAACTC-3′ and MC4R-712-Ro 5′-TGCTTTT-
TGGCTAGGATACTGAATTTAT-3′ 219-bp amplicon
detects the SNP001745712 C-allele; MC4R-712-RiT 5′-
ATTATGAATGGGTTCAAAAGGGGGTA-3 ′ and
MC4R-712-Fo 5′-GTCGGTTCAACTTACGATACGTT-
AAACT-3′ 242-bp amplicon detects the SNP001745712
T-allele. Amplicon length of the two outer primers
(MC4R-712-Fo and MC4R-712-Ro) was 406 bp. (c)
SNP001745713 CrT; MC4R-713-FiC 5′-ATCCTCTCT-
GTTTTTCAGGTATTTTCAC-3′ and MC4R-713-Ro 5′-
GCCAGGTTCATTCTTATGTAAAAGACAT-3′ 197-bp
amplicon detects the SNP001745713 C-allele; MC4R-
713-RiT 5′-TAAGAACCCAGCCAGTAGTGGTTAAA-
3′ and MC4R-713-Fo 5′-AGAATGCAGCTTATTAT-
TTTCCTGAGTT-3′ 285-bp amplicon detects the
SNP001745711 T-allele. Amplicon length of the two
outer primers (MC4R-713-Fo and MC4R-713-Ro) was
428 bp. (d) SNP002901655 GrC; MC4R-655-FiG 5′-
CCAGAGGATGTCATGCAATAAACTTGG-3 ′ and
MC4R-655-Ro 5′-CATGAGCATTTGAAGACCCT-
GTAAATCC-3′ 218-bp amplicon detects the
SNP002901655 G-allele; MC4R-655-RiC 5′-TACTCTT-
CAAGAAGTGGCTGTGGATGG-3′ and MC4R-655-Fo
5′-TTCTCATTTCACATGAAAATGACTTGCTG-
3′ 256-bp amplicon detects the SNP002901655 C-allele.
Amplicon length of the two outer primers (MC4R-655-
Fo and MC4R-655-Ro) was 420 bp. PCR-RFLP was per-
formed for genotyping SNP 001745711 CrT. Primers
were derived from the genomic sequence rcAC091576
(National Center for Biotechnology Information) as fol-
lows: MC4R-711-F 5′-CACCAGTCTTGGCTTGATA-
AGT-3′ andMC4R-711-R 5′-ACCCAGCCAGTAGTGG-
TTCA-3′ (amplicon: 385 bp), the SNP001745711 T-allele
was digested by EarI (fragment length: 222 bp and 163
bp). All PCR amplicons (RFLP or tetra-ARMS) were vi-
sualized on 2.5% agarose gels stained with ethidium bro-
mide. For validity of the genotypes, allele determination
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was made independently by at least two experienced in-
dividuals. Discrepancies were solved unambiguously ei-
ther by reaching consensus or by repeating. In addition,
we checked forMendelian inconsistencies in the trioswith
the program Pedcheck (O’Connell and Weeks 1998).
Appendix D
Genomic Sequencing
We used a nested PCR approach. A genomic region
of 4,005 bp including MC4R was covered by three over-
lapping PCR products, referred to as “upstream region”
(1.877 bp), “coding sequence” (CDS) (1,697 bp), and
“downstream region” (1,447 bp). We performed six
nested PCRs on PCR products of the upstream region and
four each on the CDS and downstream region. Nested
PCR products were sequenced by use of PCR primers and
BigDye Terminator Cycle Sequencing, version 2.0 kit (Ap-
plied Biosystems). Sequencing reactions were electropho-
resed on ABI 377 automated sequencers. Base calling was
performed using Phred (Ewing et al. 1998). Sequence as-
sembly was done using Phrap. Trace ﬁles were inspected
visually in gap4 (Bonﬁeld et al. 1995).
For the SNP001745714 ArC described elsewhere (Ja-
cobson et al. 2002), only the homozygous V103 carrier
was heterozygous, whereas all of the I103 carriers were
homozygous for the major allele A. Thus, the TDT re-
sults for V103I cannot be explained by this SNP, and it
was not further investigated. SNPs 001745712 and
001745713 were investigated in a subgroup of 336 trios,
in whom their minor alleles occurred more frequently
than did I103 (minor allele frequencies of 13.2% and
32.4%, respectively, in the parents), and displayed trans-
mission rates ∼50%.
Appendix E
Functional Studies
In our functional studies performed in Berlin andMar-
burg, the cDNAs of the wild-type MC4R and of the
V103I polymorphism were subcloned into the eukar-
yotic expression vector pSG5 (Stratagene). cDNA inserts
in the expression plasmids were characterized by restric-
tion endonuclease digestion and subsequent dideoxy se-
quencing (Perkin Elmer; Sequencer 310; PE Biosystems).
For functional assays, COS-7 cells were grown as de-
scribed elsewhere (Hinney et al. 2003). For transfections,
COS-7 cells were split into 12-well plates ( cells51.5# 10
per well) and were transfected with 0.5 mg of plasmid
DNA per well by use of Metafectene (Biontex). cAMP
measurements were performed 2 d after transfection, as
described elsewhere (Biebermann et al. 1997; Hinney et
al. 2003). EC50 and Emax values were obtained from
NDP-a-MSH, a-MSH, and b-MSH concentration-re-
sponse curves.
For cell surface–binding studies, cells were transfected
with Metafectin in 10-cm dishes. Cells were trypsinated
1 d later and were seeded in 48-well plates. Cells were
incubated overnight 48 h later, with increasing amounts
of NDP-a-MSH and 125I-labeled NDP-a-MSH. After
washing, speciﬁcally bound NDP-a-MSH was measured.
Appendix F
Statistical Analyses
TDTs: In our analyses of 520 trios and the subgroups
of 501 and 336 trios, we performed TDTs for the single
SNPs (Spielman et al. 1993) and the haplotypes consisting
of several SNPs. P values were calculated using the exact
two-sided McNemar test.
Genotype relative risk: The genotype relative risk of
obesity for I103 carriers, conditional on the parental
genotypes and a 95% exact binomial CI, were esti-
mated from the 520 trios (Schaid and Sommer 1994).
These estimates are valid under the assumption of ran-
dom mating and Hardy-Weinberg equilibrium.
Meta-analysis: We combined data from 14 study
groups. Special attention was given to the fact that the
study groups of Farooqi et al. (total obese group pub-
lished in 2003, nonobese group in 2000) and Hinney et
al. (total obese and nonobese groups published in 2003)
were reported more than once, because of enlarged sam-
ples in later analyses. The frequency of I103 carriers in
similar weight groups varies across studies. Therefore,
we did not consider studies that reported V103I status
only for one weight group. Origin, sampling criteria, and
sample size of the study groups are given in table 1. A
stratiﬁed analysis was performed in SAS, and we present
Mantel-Haenszel estimates of the OR and the respective
CIs. In addition, the Breslow-Day test for homogeneity
(Breslow and Day 1980) was conducted, to investigate
if there are differences between the study groups. Be-
cause our previous study (Hinney et al. 2003) included
the 520 obese offspring of the trios used in the TDT, we
also performed a meta-analysis without those individ-
uals, reducing the number of obese individuals in this
single study from 808 to 288 individuals; this meta-
analysis also resulted in a signiﬁcant OR of 0.69 (95%
CI 0.49–0.97; ).Pp .03
Electronic-Database Information
The URLs for data presented herein are as follows:
National Center for Biotechnology Information, http://www
.ncbi.nlm.nih.gov/
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Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for MC4R and obesity)
Phrap, http://www.phrap.org/phrap.docs/phrap.html
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